Another Major Pipeline Setback for Eli Lilly

Another Major Pipeline Setback for Eli Lilly

This episode of The Motley Fool's Market Checkup drills down on the days hottest headlines, including disappointing cancer drug results, a hot new way to fight high cholesterol, and potential problems out of Europe for medical device companies.

In this video, health-care analyst David Williamson discusses today's mixed bag of results for Eli Lilly investors. Shares of the big pharma traded down after ramucirumab met its primary endpoints in a phase 3 trial for stomach cancer, but not in breast cancer.

Watch Market Checkup and find out why the surprise failure in treating breast cancer was so important, why the gastric cancer results may not be as good as the headlines, and what Eli Lilly's next moves are for this critical late-stage asset.

Finding rock-solid dividend stocks
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report, "Secure Your Future With 9 Rock-Solid Dividend Stocks," outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

Follow David on Twitter: @MotleyDavid.

The article Another Major Pipeline Setback for Eli Lilly originally appeared on

David Williamson owns shares of Eli Lilly. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published